Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals

Monocytosis may occur in numerous inflammatory conditions but is also the defining feature of chronic myelomonocytic leukemia (CMML). Clonal somatic mutations detectable in CMML may occur with ageing in otherwise healthy individuals, so-called “clonal hematopoiesis” (CH). We investigated whether the...

Full description

Saved in:
Bibliographic Details
Published in:Blood advances 2022-07, Vol.6 (14), p.4174-4184
Main Authors: van Zeventer, Isabelle A., de Graaf, Aniek O., Koorenhof-Scheele, Theresia N., van der Reijden, Bert A., van der Klauw, Melanie M., Dinmohamed, Avinash G., Diepstra, Arjan, Schuringa, Jan Jacob, Malcovati, Luca, Huls, Gerwin, Jansen, Joop H.
Format: Article
Language:English
Subjects:
ageing
chronic myelomonocytic leukemia
Clonal hematopoiesis
elderly
monocytosis
Myeloid Neoplasia
somatic mutations
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Monocytosis may occur in numerous inflammatory conditions but is also the defining feature of chronic myelomonocytic leukemia (CMML). Clonal somatic mutations detectable in CMML may occur with ageing in otherwise healthy individuals, so-called “clonal hematopoiesis” (CH). We investigated whether the combination of CH and monocytosis would represent an early developmental stage of CMML. We studied community-dwelling individuals with monocytosis (≥ 1 x 109/L and ≥10% of leukocytes) in the population-based Lifelines cohort (n=144676 adults). The prevalence and spectrum of CH were evaluated for individuals ≥60 years with monocytosis (n=167, 0.8%) and controls 1:3 matched for age and sex (n=501). Diagnoses of hematological malignancies were retrieved by linkage to the Netherlands Cancer Registry. Monocyte counts and the prevalence of monocytosis increased with advancing age. Older individuals with monocytosis more frequently carried CH (50.9% versus 35.5%, P
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2021006755